Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...

FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.

The White House outlined plans to force down prices of drugs sold in the US using the threat of tying costs to rates paid by ...

New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...

Pres­i­dent Don­ald Trump said he’ll take ex­ec­u­tive ac­tion to have the US pay no more than oth­er coun­tries for drugs, a ...